Table S2. Percentage of DC subsets in B-/- mice treated with TLR agonist and/or RT.

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment  (n=5/group) | Conventional DCs (CD11C+B220-NK1.1-) | Plasmacytoid DCs (CD11c+B220+NK1.1-) | NKDCs  (CD11c+B220-NK1.1+) |
| NT | 65.6±8.3\* | 5.1±1.3 | 24.3±9.7 |
| Control oligo | 48.2±6.6 | 4.8±2.5 | 41.3±5.7 |
| TLR9 agonist | 30.9±9.4 (\*\*\*) | 1.9±0.5 | 64.4±3.4(\*\*\*) |
| RT | 39.1±3.0 (\*\*\*) | 2.4±1.0 | 33.6±8.1 |
| RT+TLR9 agonist | 33.9±6.9 (\*\*) | 1.7±0.7 | 58.6±5.8(\*\*\*) |

\*Number represents the percentage of a subset within total splenic DCs (CD11c+).